KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.
The heavy selling pressure might have exhausted for Regeneron (REGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
REGN maintains momentum as Eylea HD gains traction and Dupixent maintains momentum, even as lead drug Eylea faces challenges.